EpilepsyGTx y Viralgen impulsan un programa de terapia génica con vectores AAV para la epilepsia

PartnershipEPY201Positive

AI Analysis

Summary

EpilepsyGTx and Viralgen announced a collaboration to advance EPY201, an AAV-based gene therapy for focal refractory epilepsy, with Viralgen providing scalable manufacturing support ahead of initial human trials.

Clinical Trial Data

Phase

Pre-clinical/IND-enabling

Importance:6/10

Sentiment:

0.60

Gene therapyAAV vectorEpilepsyManufacturing partnershipCDMO

Read the original article

Published by PR Newswire Clinical Trials on September 9, 2026 9:56 AM

Read Original